Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. - Wikidata - awgldk - TriplyDB

Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans.

Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans.

http://www.wikidata.org/entity/Q33426587

about

Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome The Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A Review Brain-gut axis: from basic understanding to treatment of IBS and related disorders Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome Current gut-directed therapies for irritable bowel syndrome.Reproducibility and performance characteristics of colonic compliance, tone, and sensory tests in healthy humans Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort.Review article: new receptor targets for medical therapy in irritable bowel syndrome Treating irritable bowel syndrome: overview, perspective and future therapies.Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review.Opioids and the gut: pharmacology and current clinical experience.Preclinical studies of opioids and opioid antagonists on gastrointestinal function.Gastric motor and sensory functions in obesity.Frontiers in functional dyspepsia.Treatments targeting putative mechanisms in irritable bowel syndrome.Challenges in drug development for functional gastrointestinal disorders. Part II: visceral pain.Irritable bowel syndrome: update on colonic neuromuscular dysfunction and treatment.Irritable bowel syndrome and chronic constipation: emerging drugs, devices, and surgical treatments.Drug development for the irritable bowel syndrome: current challenges and future perspectives Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome.High body mass alters colonic sensory-motor function and transit in humans.Updates on treatment of irritable bowel syndrome.Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.Satiety testing: ready for the clinic?6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.Regional Colonic Transit Pattern Does Not Conclusively Identify Evacuation Disorders in Constipated Patients with Delayed Colonic Transit Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome.Kappa opioids and the modulation of pain.Gastrointestinal targets of appetite regulation in humans.Emerging pharmacologic therapies for irritable bowel syndrome.Review article: the role of gastric motility in the control of food intake.Drug discovery approaches to irritable bowel syndrome.Current and Emerging Medical Therapies for Gastroparesis.Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications.Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design Simplifying the measurement of gastric accommodation using SPECT.Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia.Pharmacological evaluation of NSAID-induced gastropathy as a "Translatable" model of referred visceral hypersensitivity.Differential effect of opioids in patients with chronic pancreatitis: an experimental pain study.

P2860

Q24644669-B4BD22C2-90BE-48BA-A024-7323F7ABC8DD Q24684839-4D306408-38F5-44C3-8494-E37FD7B9D0AC Q26851158-75EFEA92-5DE9-4EF5-832F-649DF023CBA7 Q27024801-65374473-3291-4203-A4A6-0EFD1A77A06E Q28244460-F698DF2C-7E07-4971-B7C6-CC25DB7FD1FD Q33435562-7022959A-3F83-471B-A566-DE5B6D630EB9 Q33665390-F5081107-312A-436B-A241-27991DCF0A62 Q33780866-5A1CD0CB-7282-4530-A23F-263DFFB80B2B Q33959307-9D973CA7-B2FA-4754-B3F7-47AC5D47D8B2 Q35047051-D06F7ECE-6076-42BC-B540-55ED43486353 Q35752958-9644331B-5222-421A-8BB8-782C2EE475D7 Q35860904-FD42DBFB-981B-4C85-9DAE-BCF136B351C7 Q35882832-22410C9C-7B41-4831-8D09-F0F9C648E1CD Q36099904-E038A266-E743-4116-B375-4B1D70A923B4 Q36206694-106F97A1-0D45-4681-ACC5-8E948AC95535 Q36304083-2552068D-E277-4FE8-8E63-C64A75A51BF6 Q36455907-99CC5920-2223-4F13-ACCA-5A1109DD2F91 Q36556549-E32C9424-2271-4A08-A11D-3B47395C3EE0 Q36556552-14E4630A-7B4D-4B5F-BA18-544B02B6DD90 Q36579818-10324657-29C3-4533-BF52-832E14293024 Q36808881-6830619D-C9A3-4DFD-9212-68FE1560BB68 Q36846509-D167F06E-4F8E-46E6-9D8B-F10D506D1975 Q37156627-8A7911BD-4532-4E9B-8F69-1DD6909B9B9B Q37200907-DAB51FE2-B126-47B8-B8E2-B9B4290DC294 Q37273648-1A97FE64-8B29-4D09-8E63-5E22F47E042F Q37444418-51A21D6E-911F-45C2-8848-2DF56FAACE8E Q37564153-19977C7A-C4CD-4810-91C4-BE43FB527833 Q37624734-85A976EC-E76F-40DA-AE91-5940F410E115 Q37725698-7F30B329-6DF1-4C97-AAA1-CFFCE7897484 Q37740221-136E3E33-9E6E-4DFF-84E2-225677DD3314 Q37778790-18A8AB37-4B2C-4366-9268-87B955CBEA71 Q37845906-668EB9C4-4CF5-4471-A78A-E2A2696D51E7 Q38550878-14046507-0B58-414F-93A1-9D5B1510D2A9 Q38617535-31F32954-C5B2-46B0-884A-F69CBA88DDC8 Q38911748-035C7F2A-669E-40FF-B520-516DC255646B Q39522869-9B0A50FB-138E-40F9-8905-F48F6CE5E154 Q40771921-57E6649C-B263-4BAE-B1C5-4AB6325E4049 Q41979327-8EF87D61-DCA4-4B9F-8430-E89DA07CB11F Q42013293-BC41ADAC-C278-4280-9C21-AFC7F0ADAE70 Q42167015-8E3E74D4-5B81-4A75-81C1-6832D3E38F97

P2860

Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans.

http://www.wikidata.org/entity/Q33426587

description

2003 nî lūn-bûn

@nan

2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Effects of a kappa-opioid agon ...... d sensory functions in humans.

@ast

Effects of a kappa-opioid agon ...... d sensory functions in humans.

@en

type

label

Effects of a kappa-opioid agon ...... d sensory functions in humans.

@ast

Effects of a kappa-opioid agon ...... d sensory functions in humans.

@en

prefLabel

Effects of a kappa-opioid agon ...... d sensory functions in humans.

@ast

Effects of a kappa-opioid agon ...... d sensory functions in humans.

@en

P1433

Q33426587-6CFC275B-A207-4BCE-8EBD-2E47510905F7

P1476

Q33426587-DE261106-4C47-4910-8FC0-A7A60DC2BF1B

P2093

Q33426587-1CE1A507-25B9-4ADB-B350-185DC2865390

Q33426587-4CB78FC5-BF38-482A-9902-B3D3077A0D05

Q33426587-7C822D36-5DF1-4CD1-A20E-9A0F053AA55F

Q33426587-86235F7C-66C1-4546-A1C1-EB525511E4B7

Q33426587-8C45529E-BEAF-4660-8000-184B434B3A1E

Q33426587-9CF833DE-49D8-4B79-9AC1-B34D80C55F30

Q33426587-A76B8DB1-CA58-4368-8E75-48E0D857C501

P2860

Q33426587-07D9430F-9004-4285-BC05-BAFF96B93996

Q33426587-10499783-29C1-4C72-B164-EB0F49DCC336

Q33426587-16E964E2-C969-424A-8AF0-7EC041457135

Q33426587-1FEA5D9C-B9F0-4B77-A375-1962C7A1896A

Q33426587-243EA423-CCAE-4FDA-9804-2FCD4D31895B

Q33426587-244FA23D-E18A-42BB-9894-19231DE62531

Q33426587-2DE50171-CAA3-4A55-AEAD-C712C3CCE759

Q33426587-3030B6F7-1CF1-4E6C-B122-FA57559B7D52

Q33426587-36686D40-E382-4B9C-8EFF-3CD6662D911F

Q33426587-39E37286-542B-45D6-A14F-00BAB25A5C64

P304

Q33426587-ECECAF62-686E-4493-AD70-4AD5B6ECF0AD

P31

Q33426587-404AA40A-51C7-4F25-A98E-7A3030F80DE1

P356

Q33426587-5F185351-6463-4D0C-865F-9DA5988A8660

P433

Q33426587-78CF1950-7E44-4561-9178-00B5AF317626

P478

Q33426587-F7B4CD40-3CEA-4BB1-873C-DF0F387B615F

P50

Q33426587-12553B61-AA78-41D6-827C-6F9149AAD7FE

Q33426587-6EED7BCD-66BC-4015-BC9E-E779BEF9ED62

Q33426587-A3C66F09-6450-4293-9DB5-A71029ACA603

P577

Q33426587-E5DD98B2-7835-4AEF-A924-1D827B11313C

P5875

Q33426587-6A277BEF-109C-4865-AA65-81A6AEC45D27

P698

Q33426587-5CEA8624-279F-42D8-8573-E6FE770C8662

P921

Q33426587-669b67ce-04b7-4973-a2b8-45bcdc4ee148

P356

AJPGI.00360.2002

P1433

American Journal of Physiology - Gastrointestinal and Liver Physiology

P1476

Effects of a kappa-opioid agon ...... d sensory functions in humans.

@en

P2093

Duane D Burton

http://www.w3.org/2001/XMLSchema#string

Frank T Weber

http://www.w3.org/2001/XMLSchema#string

Heather J Chial

http://www.w3.org/2001/XMLSchema#string

Irene Ferber

http://www.w3.org/2001/XMLSchema#string

Jutta Jacob

http://www.w3.org/2001/XMLSchema#string

Sanna McKinzie

http://www.w3.org/2001/XMLSchema#string

Silvia Delgado-Aros

http://www.w3.org/2001/XMLSchema#string

P2860

kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system

Strategies to manage the adverse effects of oral morphine: an evidence-based report.

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact.

Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans.

Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia.

Enkephalin inhibits release of substance P from sensory neurons in culture and decreases action potential duration

Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons.

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study.

Effects of naltrexone on food intake and changes in subjective appetite during eating: evidence for opioid involvement in the appetizer effect.

Contrasting actions of intrathecal U50,488H, morphine, or [D-Pen2, D-Pen5] enkephalin or intravenous U50,488H on the visceromotor response to colorectal distension in the rat.

P304

G558-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPGI.00360.2002

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

284

http://www.w3.org/2001/XMLSchema#string

P50

Alan R. Zinsmeister

Lawrence A. Szarka

Michael Camilleri

P577

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10860278

http://www.w3.org/2001/XMLSchema#string

P698

12631557

http://www.w3.org/2001/XMLSchema#string

P921